borderline significanceP = 0.06
Patients in the MCS‐BTT group received everolimus more infrequently than those in the control group with a borderline significance, both at post‐HTx year‐1 (27% vs. 43%, P = 0.06) and at post‐HTx year‐3 (28% vs. 47%, P = 0.05).